Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.85
+0.64 (12.28%)
Market open: Aug 12, 2026, 1:35 PM EDT
5.12
-0.23 (-4.31%)
Previous after-hours: Aug 11, 2026, 5:10 PM EDT
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, CEO & Chairman |
| Ms. Denise Carter | Co-Founder, COO & Director |
| Ms. Sally Lawlor | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-16 | DEF 14A | tm265038-3_def14a.htm |
| 2026-07-16 | ARS | tm2620037d2_ars.pdf |
| 2026-07-06 | PRE 14A | tm265038-1_pre14a.htm |
| 2026-06-23 | 8-K | tm2618505d1_8k.htm |
| 2026-06-04 | 8-K | tm2616916d1_8k.htm |
| 2026-05-07 | 8-K | tm2613938d1_8k.htm |
| 2026-05-07 | 10-Q | qnrx-20260331x10q.htm |
| 2026-03-26 | 8-K | tm269662d1_8k.htm |
| 2026-03-26 | 10-K | qnrx-20251231x10k.htm |
| 2026-03-11 | 8-K | tm268576d1_8k.htm |